Novo Nordisk Receives EU Approval for Wegovy Pill

Novo Nordisk has received approval from the European Union (EU) for its oral medication Wegovy, developed for weight management. This approval is seen as a significant step in the company's strategy to expand its product portfolio in the obesity treatment field. The pill form of Wegovy aims to offer patients a more convenient alternative to the injection form. The EU approval could enhance Novo Nordisk's competitive position in the weight management market. The company had previously captured a significant market share with the injectable form of Wegovy. The approval of the oral form may positively impact sales by improving patient compliance. With this approval, Novo Nordisk aims to meet the growing demand for obesity treatment in Europe. The company expects a notable increase in revenue following the launch of the Wegovy pill. However, the pricing and reimbursement conditions for the drug have not yet been finalized. This is not investment advice.

📊 NVO — Piyasa Yorumu

▲ up · 70%

The news that Novo Nordisk has received EU approval for its Wegovy pill reinforces the company's leadership in the weight loss treatment space. Technical indicators support this positive development: the RSI at 65 is not yet in overbought territory, and the MACD remains above its signal line, maintaining a bullish trend. The price is trading above both the 20-day and 50-day moving averages, suggesting upward momentum could continue in the short term. However, caution is warranted as the approval news may already be priced in.

RSI 14

65.0

MACD

0.30

24h Δ

2.46%

📊 GOOGL — Piyasa Yorumu

▲ up · 60%

GOOGL shares rose nearly 5% in the last close, with the RSI entering overbought territory at 71.8. The MACD line is above the signal line and in positive territory, indicating strong short-term momentum. The price is trading well above both the 20-day and 50-day moving averages. However, since the news headline is not directly related to GOOGL, the impact may be limited. Given the overbought conditions and the lack of relevant news, upside expectations should be approached with caution.

RSI 14

71.8

MACD

3.10

24h Δ

4.98%

Canlı Grafikler